Tech Company Financing Transactions
Ocular Therapeutix Funding Round
Ocular Therapeutix closed a $23.8 million Series D funding round on 1/28/2013. Investors included Ascension Ventures, Polaris Partners and Sparta.
Transaction Overview
Company Name
Announced On
1/28/2013
Transaction Type
Venture Equity
Amount
$23,800,000
Round
Series D
Investors
Proceeds Purpose
Ocular Therapeutix will use the funds to further advance development activities and implementation of clinical trials for its sustained release drug programs, including travoprost for the treatment of glaucoma, and dexamethasone for the resolution of post-operative inflammation and pain. The funds will also be used to support U.S. commercial launch efforts and to develop sustained release therapies for retinal diseases in collaboration with pharma partners.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
24 Crosby Dr.
Bedford, MA 01730
USA
Bedford, MA 01730
USA
Phone
Website
Email Address
Overview
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a company focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology and ophthalmic surgery.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 1/28/2013: ChaCha Search venture capital transaction
Next: 1/28/2013: Siluria Technologies venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs